These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38900374)

  • 1. Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.
    Coperchini F; Greco A; Petrosino E; Croce L; Teliti M; Marchesi N; Pascale A; Calì B; Pignatti P; Magri F; Uddin M; Rotondi M
    J Endocrinol Invest; 2024 Jun; ():. PubMed ID: 38900374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.
    Awwad O; Coperchini F; Pignatti P; Denegri M; Massara S; Croce L; Di Buduo CA; Abbonante V; Balduini A; Chiovato L; Rotondi M
    J Endocrinol Invest; 2018 Nov; 41(11):1275-1282. PubMed ID: 29546654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug.
    Coperchini F; Greco A; Croce L; Pignatti P; Muzza M; Petrosino E; Teliti M; Magri F; Rotondi M
    Biomed Pharmacother; 2024 Jan; 170():115974. PubMed ID: 38056240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
    Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
    Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFOA, PFHxA and C6O4 differently modulate the expression of CXCL8 in normal thyroid cells and in thyroid cancer cell lines.
    Coperchini F; De Marco G; Croce L; Denegri M; Greco A; Magri F; Tonacchera M; Imbriani M; Rotondi M; Chiovato L
    Environ Sci Pollut Res Int; 2023 May; 30(23):63522-63534. PubMed ID: 37052835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes.
    Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Magri F; Chiovato L; Rotondi M
    Oncotarget; 2019 Nov; 10(60):6432-6443. PubMed ID: 31741708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D Reduces Thyroid Cancer Cells Migration Independently From the Modulation of CCL2 and CXCL8 Chemokines Secretion.
    Coperchini F; Greco A; Croce L; Petrosino E; Grillini B; Magri F; Chiovato L; Rotondi M
    Front Endocrinol (Lausanne); 2022; 13():876397. PubMed ID: 35498406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion.
    Coperchini F; Pignatti P; Leporati P; Carbone A; Croce L; Magri F; Chiovato L; Rotondi M
    Endocrine; 2016 Oct; 54(1):123-128. PubMed ID: 26450713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
    Rotondi M; Coperchini F; Awwad O; Pignatti P; Di Buduo CA; Abbonante V; Magri F; Balduini A; Chiovato L
    Mediators Inflamm; 2016; 2016():8512417. PubMed ID: 27555670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
    J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
    O'Byrne PM; Metev H; Puu M; Richter K; Keen C; Uddin M; Larsson B; Cullberg M; Nair P
    Lancet Respir Med; 2016 Oct; 4(10):797-806. PubMed ID: 27574788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do PFCAs drive the establishment of thyroid cancer microenvironment? Effects of C6O4, PFOA and PFHxA exposure in two models of human thyroid cells in primary culture.
    Coperchini F; Greco A; Croce L; Teliti M; Calì B; Chytiris S; Magri F; Rotondi M
    Environ Int; 2024 May; 187():108717. PubMed ID: 38728818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
    Rotondi M; Coperchini F; Pignatti P; Magri F; Chiovato L
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E427-32. PubMed ID: 25590211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.
    Coperchini F; Pignatti P; Carbone A; Bongianino R; Di Buduo CA; Leporati P; Croce L; Magri F; Balduini A; Chiovato L; Rotondi M
    Tumour Biol; 2016 Apr; 37(4):5569-75. PubMed ID: 26577851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
    Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
    Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina.
    Goczalik I; Ulbricht E; Hollborn M; Raap M; Uhlmann S; Weick M; Pannicke T; Wiedemann P; Bringmann A; Reichenbach A; Francke M
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4578-89. PubMed ID: 18552386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.
    Ha H; Bensman T; Ho H; Beringer PM; Neamati N
    Br J Pharmacol; 2014 Mar; 171(6):1551-65. PubMed ID: 24354854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.